Logo image of HIVE

HIVE DIGITAL TECHNOLOGIES LT (HIVE) Stock Fundamental Analysis

NASDAQ:HIVE - Nasdaq - CA4339211035 - Common Stock - Currency: USD

2.27  +0.04 (+1.79%)

Premarket: 2.33 +0.06 (+2.64%)

Fundamental Rating

4

Taking everything into account, HIVE scores 4 out of 10 in our fundamental rating. HIVE was compared to 282 industry peers in the Software industry. The financial health of HIVE is average, but there are quite some concerns on its profitability. HIVE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

HIVE had negative earnings in the past year.
HIVE had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: HIVE reported negative net income in multiple years.
In the past 5 years HIVE always reported a positive cash flow from operatings.
HIVE Yearly Net Income VS EBIT VS OCF VS FCFHIVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

HIVE has a better Return On Assets (-0.56%) than 62.41% of its industry peers.
Looking at the Return On Equity, with a value of -0.67%, HIVE is in the better half of the industry, outperforming 64.89% of the companies in the same industry.
Industry RankSector Rank
ROA -0.56%
ROE -0.67%
ROIC N/A
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
HIVE Yearly ROA, ROE, ROICHIVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

HIVE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HIVE Yearly Profit, Operating, Gross MarginsHIVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

5

2. Health

2.1 Basic Checks

HIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
HIVE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HIVE has been increased compared to 5 years ago.
Compared to 1 year ago, HIVE has an improved debt to assets ratio.
HIVE Yearly Shares OutstandingHIVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
HIVE Yearly Total Debt VS Total AssetsHIVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 3.02 indicates that HIVE is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.02, HIVE is in line with its industry, outperforming 57.09% of the companies in the same industry.
HIVE has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
HIVE has a Debt to Equity ratio of 0.04. This is comparable to the rest of the industry: HIVE outperforms 59.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 3.02
ROIC/WACCN/A
WACC9.94%
HIVE Yearly LT Debt VS Equity VS FCFHIVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

HIVE has a Current Ratio of 3.72. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.
HIVE has a Current ratio of 3.72. This is amongst the best in the industry. HIVE outperforms 81.91% of its industry peers.
HIVE has a Quick Ratio of 3.72. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 3.72, HIVE belongs to the best of the industry, outperforming 81.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.72
Quick Ratio 3.72
HIVE Yearly Current Assets VS Current LiabilitesHIVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.75% over the past year.
The Earnings Per Share has been decreasing by -3.68% on average over the past years.
HIVE shows a small growth in Revenue. In the last year, the Revenue has grown by 0.71%.
HIVE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.18% yearly.
EPS 1Y (TTM)78.75%
EPS 3Y-3.68%
EPS 5YN/A
EPS Q2Q%102.65%
Revenue 1Y (TTM)0.71%
Revenue growth 3Y19.73%
Revenue growth 5Y29.18%
Sales Q2Q%-15.51%

3.2 Future

The Earnings Per Share is expected to grow by 41.15% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 42.54% on average over the next years. This is a very strong growth
EPS Next Y69.3%
EPS Next 2Y43.28%
EPS Next 3Y41.15%
EPS Next 5YN/A
Revenue Next Year2.92%
Revenue Next 2Y64.95%
Revenue Next 3Y65.98%
Revenue Next 5Y42.54%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HIVE Yearly Revenue VS EstimatesHIVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
HIVE Yearly EPS VS EstimatesHIVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HIVE. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 84.27, which means the current valuation is very expensive for HIVE.
The rest of the industry has a similar Price/Forward Earnings ratio as HIVE.
HIVE is valuated expensively when we compare the Price/Forward Earnings ratio to 36.44, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 84.27
HIVE Price Earnings VS Forward Price EarningsHIVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HIVE Per share dataHIVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

HIVE's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
HIVE's earnings are expected to grow with 41.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.28%
EPS Next 3Y41.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HIVE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HIVE DIGITAL TECHNOLOGIES LT

NASDAQ:HIVE (7/21/2025, 8:05:57 PM)

Premarket: 2.33 +0.06 (+2.64%)

2.27

+0.04 (+1.79%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)06-26 2025-06-26/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners17.39%
Inst Owner Change1.4%
Ins Owners0.28%
Ins Owner Change0%
Market Cap486.46M
Analysts80
Price Target4.27 (88.11%)
Short Float %4.31%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.3%
Min Revenue beat(2)-1.52%
Max Revenue beat(2)6.13%
Revenue beat(4)2
Avg Revenue beat(4)3.4%
Min Revenue beat(4)-8.08%
Max Revenue beat(4)17.08%
Revenue beat(8)5
Avg Revenue beat(8)3.72%
Revenue beat(12)8
Avg Revenue beat(12)17.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.02%
PT rev (3m)-25.84%
EPS NQ rev (1m)13.04%
EPS NQ rev (3m)13.04%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-11.94%
Revenue NQ rev (3m)-11.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 84.27
P/S 4.22
P/FCF N/A
P/OCF 29.24
P/B 1.08
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)0.03
Fwd EY1.19%
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)0.08
OCFY3.42%
SpS0.54
BVpS2.1
TBVpS2.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.56%
ROE -0.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.49%
ROA(5y)-16.27%
ROE(3y)-49.77%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 187.21%
Cap/Sales 104.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.72
Quick Ratio 3.72
Altman-Z 3.02
F-Score4
WACC9.94%
ROIC/WACCN/A
Cap/Depr(3y)97.27%
Cap/Depr(5y)157.57%
Cap/Sales(3y)54.64%
Cap/Sales(5y)58.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.75%
EPS 3Y-3.68%
EPS 5YN/A
EPS Q2Q%102.65%
EPS Next Y69.3%
EPS Next 2Y43.28%
EPS Next 3Y41.15%
EPS Next 5YN/A
Revenue 1Y (TTM)0.71%
Revenue growth 3Y19.73%
Revenue growth 5Y29.18%
Sales Q2Q%-15.51%
Revenue Next Year2.92%
Revenue Next 2Y64.95%
Revenue Next 3Y65.98%
Revenue Next 5Y42.54%
EBIT growth 1Y-44.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year280.42%
EBIT Next 3Y69.4%
EBIT Next 5YN/A
FCF growth 1Y-93.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.55%
OCF growth 3Y-36.92%
OCF growth 5Y84.91%